All News

Patients with spinal muscular atrophy (SMA) treated with a more expensive medication were found to have higher pharmacy costs but lower SMA-related health care resource utilization and medical costs compared with patients receiving standard-of-care nusinersen monotherapy.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.

An analysis study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The top 5 articles about rare blood featured information on pseudo–thrombotic thrombocytopenic purpura (TTP), immune TTP, and hemophilia.

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

The most-read articles in digital health covered improved outcomes, patient management, and reduced cost of care in telehealth and app-based care.

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) explored a variety of topics concerning patients with COPD, including long-acting inhaler adherence and their risk of falling.

Just 8.5% of eligible patients were screened for hepatitis C virus (HCV); among them, 5.9% tested positive for the HCV antibody, and 3.0% had an active infection.

In 2023, the most-read articles published in The American Journal of Accountable Care® (AJAC) highlighted innovative care models, lessons learned from health system partnerships, and much more.

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.

A multivariable analysis suggested the safety and efficacy of onasemnogene abeparvovec (OA) in the treatment of older and heavier children with spinal muscular atrophy (SMA) type 1.

The top articles of 2023 addressed key issues such as representation gaps in aRCC research, concerns about the 340B program's impact on asthma disparities, slow adoption of equity innovations, potential biases in type 2 diabetes risk models, and addressing disparities in psoriasis treatment based on race and culture.

The researchers noted the need for strategies to better support women living with HIV with breast cancer during toxic therapies to improve outcomes among this growing population.

This year’s top 5 most-read articles on pulmonary arterial hypertension (PAH) explored expert opinions on treatment approaches, data on newly emerging therapies, the impacts of alcohol, and more.

Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.

The top 5 most-read articles on sleep published on AJMC.com this year include content focusing on narcolepsy management, approval of medication to treat insomnia, and the association of metabolic syndrome with sleep duration.

Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.

In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.

Two posters presented at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting evaluated real-world biologic utilization for patients with severe, uncontrolled asthma.

Our top-read type 1 diabetes articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

Excision BioTherapeutics has so far released positive safety data from the first 3 participants living with HIV-1, with no evidence of vector shedding in sexual organ tissue.

The most-viewed vaccine content for this year encompassed cost, efficacy, and skepticism surrounding vaccination, particularly targeting COVID-19.

This study found no significant associations between weight changes and outcomes in hand osteoarthritis.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

This year’s most-read articles on infectious disease explored topics like vitamin D deficiency, COVID-19 masking, and Clostridioides difficile infection.

The top read ophthalmology articles of 2023 included news on FDA approvals and the link between smoking and ocular symptoms, including age-related macular degeneration.